Schutter Richard Urbain De Acquires 4,900 Shares of Valeant Pharmaceuticals Intl Inc (VRX) Stock
Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) Director Schutter Richard Urbain De purchased 4,900 shares of Valeant Pharmaceuticals Intl stock in a transaction that occurred on Monday, August 21st. The shares were acquired at an average price of C$14.35 per share, with a total value of C$70,315.00.
Shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) traded down 4.45% during midday trading on Friday, reaching $17.62. 1,440,357 shares of the company’s stock traded hands. The firm’s market cap is $6.14 billion. The stock has a 50-day moving average price of $20.01 and a 200 day moving average price of $17.58. Valeant Pharmaceuticals Intl Inc has a 12 month low of $11.20 and a 12 month high of $40.68.
VRX has been the subject of a number of research analyst reports. Scotiabank lifted their price target on Valeant Pharmaceuticals Intl to C$19.00 and gave the stock a “sector perform” rating in a report on Wednesday, May 10th. Royal Bank Of Canada reiterated a “sector perform” rating and set a C$26.00 price target on shares of Valeant Pharmaceuticals Intl in a report on Friday, June 9th. TD Securities reduced their price target on Valeant Pharmaceuticals Intl to C$20.50 and set a “hold” rating for the company in a report on Wednesday, May 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Valeant Pharmaceuticals Intl in a report on Thursday, June 29th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Valeant Pharmaceuticals Intl currently has an average rating of “Hold” and a consensus price target of C$23.33.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc operates as a pharmaceutical and medical device company worldwide. It operates in three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The company offers Lotemax gel for the treatment of inflammation and pain following ocular surgery; Ocuvite, a lutein eye vitamin and mineral supplement; PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus products; Biotrue multi-purpose solution for healthy contact lens wear; Artelac to treat dry eyes; Boston, a cleansing solution for gas permeable contact lenses; and Bedoyecta, a vitamin B complex.
Receive News & Stock Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related stocks with our FREE daily email newsletter.